Standardized Combination Antibiotic Treatment of Mycobacterium avium Complex Lung Disease

다국어 초록 (Multilingual Abstract)

Purpose: The optimal treatment regimen for Mycobacterium avium complex (MAC) lung disease has not yet been fully established. We evaluated the efficacy of standardized combination antibiotic therapy and the factors that might affect unfavorable microbiologic responses in patients with MAC pulmonary disease.
Materials and Methods: This retrospective study reviewed data from 96 patients (56 females; median age 59 years) treated with newly diagnosed MAC lung disease between January 2003 and December 2006. Results: All patients received standardized combination antibiotic therapy, consisting of clarithromycin, rifampicin,and ethambutol. Streptomycin was additionally given in 72 patients (75%)for a median duration of 4.5 months. The overall favorable microbiologic response rate was 79% (76/96); 20 patients (21%) had unfavorable microbiologic responses,including failure to sputum conversion (n = 13), relapse (n = 3), and MACrelated death (n = 4). A positive sputum acid-fast bacillus smear at the start of treatment was an independent predictor of an unfavorable microbiologic response.
Conclusion: Standardized combination antibiotic therapy consisting of clarithromycin,rifampicin, and ethambutol with or without initial use of strepto

참고문헌 (Reference)

1 Thomson RM, "When and how to treat pulmonary non-tuberculous mycobacterial diseases" 14 : 12-26, 2009

2 Myung Jin Chung, "Thin-Section CT Findings of Nontuberculous Mycobacterial PulmonaryDiseases: Comparison Between Mycobacterium avium-intracellulareComplex and Mycobacterium abscessus Infection" 대한의학회 20 (20): 777-783, 2005

3 Nishiuchi Y, "The recovery of Mycobacterium avium-intracellulare complex (MAC) from the residential bathrooms of patients with pulmonary MAC" 45 : 347-351, 2007

4 Kobashi Y, "The microbiological and clinical effects of combined therapy according to guidelines on the treatment of pulmonary Mycobacterium avium complex disease in Japan - including a follow-up study" 74 : 394-400, 2007

5 Kobashi Y, "The effect of combined therapy according to the guidelines for the treatment of Mycobacterium avium complex pulmonary disease" 42 : 670-675, 2003

6 Clinical and Laboratory Standards Institute, "Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes;Approved Standard. 2003"

7 Kitada S, "Serodiagnosis of Mycobacterium avium complex pulmonary disease using an enzyme immunoassay kit" 177 : 793-797, 2008

8 Wallace RJ Jr, "Repeat positive cultures in Mycobacterium intracellulare lung disease after macrolide therapy represent new infections in patients with nodular bronchiectasis" 186 : 266-273, 2002

9 Koh WJ, "Pulmonary TB and NTM lung disease: comparison of characteristics in patients with AFB smear-positive sputum" 10 : 1001-1007, 2006

10 Wallace RJ Jr, "Polyclonal Mycobacterium avium complex infections in patients with nodular bronchiectasis" 158 : 1235-1244, 1998

11 Korean Academy of Tuberculosis and Respiratory Diseases (KATRD), "Nontuberculous mycobacterial lung disease. In Guideline of management of tuberculosis."

12 Field SK, "Mycobacterium avium complex pulmonary disease in patients without HIV infection" 126 : 566-581, 2004

13 Nishiuchi Y, "Mycobacterium avium complex organisms predominantly colonize in the bathtub inlets of patients’ bathrooms" 62 : 182-186, 2009

14 Yamazaki Y, "Markers indicating deterioration of pulmonary Mycobacterium avium-intracellulare infection" 160 : 1851-1855, 1999

15 Lam PK, "Factors related to response to intermittent treatment of Mycobacterium avium complex lung disease" 173 : 1283-1289, 2006

16 Marras TK, "Epidemiology of human pulmonary infection with nontuberculous mycobacteria" 23 : 553-567, 2002

17 Fujikane T, "Efficacy and outcomes of clarithromycin treatment for pulmonary MAC disease" 9 : 1281-1287, 2005

18 Tanaka E, "Effect of clarithromycin regimen for Mycobacterium avium complex pulmonary disease" 160 : 866-872, 1999

19 Griffith DE, "Early results (at 6 months) with intermittent clarithromycinincluding regimens for lung disease due to Mycobacterium avium complex" 30 : 288-292, 2000

20 ATS Board of Directors, "Diagnostic Standards and Classification of Tuberculosis in Adults and Children" 161 : 1376-1395, 2000

21 Kasperbauer SH, "Diagnosis and treatment of infections due to Mycobacterium avium complex" 29 : 569-576, 2008

22 Medical Section of the American Lung Association, "Diagnosis and treatment of disease caused by nontuberculous mycobacteria. This official statement of the American Thoracic Society was approved by the Board of Directors, March 1997" 156 : S1-25, 1997

23 Won-Jung Koh, "Diagnosis and Treatment of Nontuberculous Mycobacterial Pulmonary Diseases: A Korean Perspective" 대한의학회 20 (20): 913-925, 2005

24 Koh WJ, "Clinical significance of nontuberculous mycobacteria isolated from respiratory specimens in Korea" 129 : 341-348, 2006

25 Griffith DE, "Azithromycin-containing regimens for treatment of Mycobacterium avium complex lung disease" 32 : 1547-1553, 2001

26 Jeon K, "Antibiotic treatment of Mycobacterium abscessus lung disease: a retrospective analysis of 65 patients" 180 : 896-902, 2009

27 Griffith DE, "An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases" 175 : 367-416, 2007

28 Kobashi Y, "A double-blind randomized study of aminoglycoside infusion with combined therapy for pulmonary Mycobacterium avium complex disease" 101 : 130-138, 2007